SALOME results underscore urgent need for more treatment options, says lead researcher
The results of the ground-breaking SALOME research, published in the Journal of the American Medical Association (JAMA) Psychiatry, show chronic heroin addiction now has another effective treatment tool – hydromorphone, a licensed pain medication.
SALOME, which stands for the Study to Assess Longer-term Opioid Medication Effectiveness, found hydromorphone (HDM) to be as effective as diacetylmorphine (pharmaceutical-grade prescription heroin) for people who have not benefited from previous treatments, such as methadone or suboxone.
Led by researchers from Providence Health Care (PHC), the Centre for Health Evaluation and Outcome Sciences (CHÉOS) at St. Paul’s Hospital and the School of Population and Public Health of the University of British Columbia (UBC), it’s the only clinical trial of its kind in the world.
“Prior to SALOME, hydromorphone had never been evaluated as a substitution treatment for opioid dependence,” said SALOME Principal Investigator Dr. Eugenia Oviedo-Joekes, associate professor in the UBC School of Population and Public Health. “Hydromorphone is a widely available licensed pain medication. Our study shows that hydromorphone is as effective as diacetylmorphine, providing a licensed alternative to treat severe opioid use disorder. Providing injectable opioids in specialized clinics under supervision ensures safety of both the patients and the community, and the provision of comprehensive care.”
A total of 202 participants in Vancouver were randomized in a six-month double blind study to receive either injectable hydromorphone or injectable diacetylmorphine (DAM). The medication was administered at PHC’s Crosstown Clinic under the supervision of an interdisciplinary team of physicians, nurses, social workers and counselors.
Key findings of the research include:
- Injectable hydromorphone is as effective as injectable diacetylmorphine for long-term street opioid users not currently benefitting from available treatments (estimated to be about 10 per cent of the opioid-dependent population not currently in treatment).
- Study participants on both medications reported far fewer days of street-heroin and other opioid use at six months (three to five days per month), compared to almost daily illicit opioid use prior to being enrolled in the study.
- Participants also reported a significant reduction in days of illegal activities (from an average of 14.1 days per month to less than four).
- Almost 80% were retained in treatment at six months.
- Hydromorphone and diacetylmorphine are both safe when taken in a clinical setting. Out of a total of 88,451 injections, there were 14 overdoses and 11 seizures, all successfully managed in the clinic. If these events had occurred in the street, the outcomes may have been fatal.
SALOME started in late 2011 and concluded in late 2015. It is the follow-up study to the North American Opiate Medication Initiative (NAOMI), North America’s first-ever clinical trial of diacetylmorphine/prescription heroin as an opioid agonist treatment medication.
The SALOME study received funding from the Canadian Institutes of Health Research (CIHR) and private donors through the fundraising efforts of the InnerChange Foundation and St. Paul’s Foundation. Providence Health Care funded clinical care for participants during the study. The cost of the study was $7.4 million.
Providence Health Care (PHC) is one of Canada’s largest faith-based health care organizations, operating 17 health care facilities in Greater Vancouver. PHC operates one of two adult academic health science centres in the province – St. Paul’s Hospital – performs cutting-edge research in more than 30 clinical specialties, and focuses its services on six “populations of emphasis”: cardio-pulmonary risks and illnesses, HIV/AIDS, mental health, renal risks and illness, specialized needs in aging and urban health and is home to the B.C. Centre for Excellence in HIV/AIDS. www.providencehealthcare.org.
The Centre for Health Evaluation and Outcome Sciences: A centre of the Providence Health Care Research Institute (PHCRI) and the University of British Columbia, the Centre for Health Evaluation and Outcome Sciences (CHÉOS) is a multidisciplinary research collective founded to pursue excellence through the evaluation, interpretation, and dissemination of health outcomes information. CHÉOS works across all of PHCRI’s health disciplines, including aging, cardiopulmonary health, urban health, HIV/AIDS, mental health, and kidney health.
The University of British Columbia (UBC) is one of North America’s largest public research and teaching institutions,and is consistently ranked among the world’s 40 best universities. Surrounded by the beauty of the Canadian West, it is a place that inspires bold, new ways of thinking that have helped make it a national leader in areas as diverse as community service learning, sustainability and research commercialization. UBC offers more than 58,000 students a range of innovative programs and attracts $519 million per year in research funding from government, non-profit organizations and industry through over 8,000 projects and grants.